Anxiety disorders: under-diagnosed and insufficiently treated

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
   Google Scholar
• Nutt DJ, Ballenger JC, Sheehan D, Wittchen HU. Generalized anxiety disorder: Comorbidity, comparative biology and treatment. Int J Neuropsychopharmacol 2002; 5(4)315–25
   PubMed Web of Science ®Google Scholar
• Westenberg HG, Liebowitz MR. Overview of panic and social anxiety disorders. J Clin Psychiatry 2004; 65(Suppl 14)22–6
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Owens MJ. Treatment of mood disorders. Nat Neurosci 2002; 5(Suppl)1068–70
   PubMed Web of Science ®Google Scholar
• Pezawas L, Meyer-Lindenberg A, Drabant EM, et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: A genetic susceptibility mechanism for depression. Nat Neurosci 2005; 8(6)828–34
   PubMed Web of Science ®Google Scholar
• S Kasper, den Boer, JA, Sitsen, JMA, editors. Handbook of Depression and Anxiety. 2nd ed, revised and expanded. New York/Basel: Marcel Dekker, Inc; 2003.
   Google Scholar
• Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62(6)593–602
   PubMed Web of Science ®Google Scholar
• Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62(6)617–27
   PubMed Web of Science ®Google Scholar
• Kessler RC, Merikangas KR. The National Comorbidity Survey Replication (NCS-R): Background and aims. Int J Methods Psychiatr Res 2004; 13(2)60–8
   PubMed Web of Science ®Google Scholar
• Dunner DL. Management of anxiety disorders: The added challenge of comorbidity. Depress Anxiety 2001; 13(2)57–71
   PubMed Web of Science ®Google Scholar
• Rasmussen SA, Eisen JL. The epidemiology and clinical features of obsessive compulsive disorder. Psychiatr Clin North Am 1992; 15(4)743–58
   PubMed Web of Science ®Google Scholar
• Brawman-Mintzer O, Lydiard RB, Emmanuel N, et al. Psychiatric comorbidity in patients with generalized anxiety disorder. Am J Psychiatry 1993; 150(8)1216–8
   Google Scholar
• Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1995; 52(12)1048–60
   PubMed Web of Science ®Google Scholar
• Wittchen, HU, Essau, CA, Krieg, JC. Anxiety disorders: similarities and differences of comorbidity in treated and untreated groups. Br J Psychiatry. 1991; Suppl 12:23–33.
   Google Scholar
• Wittchen HU, Lieb R, Wunderlich U, Schuster P. Comorbidity in primary care: presentation and consequences. J Clin Psychiatry 1999; 60(Suppl 7)29–36
   PubMed Web of Science ®Google Scholar
• Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51(1)8–19
   PubMed Web of Science ®Google Scholar
• Katzelnick DJ, Kobak KA, DeLeire T, et al. Impact of generalized social anxiety disorder in managed care. Am J Psychiatry 2001; 158(12)1999–2007
   PubMed Web of Science ®Google Scholar
• Wang PS, Berglund P, Olfson M, et al. Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62(6)603–13
   PubMed Web of Science ®Google Scholar
• Kasper, S. Neurobiology and new psychopharmacological strategies for treatment of anxiety disorders. In:. G Darcourt, Mendlewicz, J, Racagni, G, Brunello, N, editors. Current therapeutical approaches to panic and other anxiety disorders. vol, 8. Basel: Int Acad Biomed Drug Res., Karger; 1994. p, 15–35.
   Google Scholar
• Kasper S. Social phobia: The nature of the disorder. J Affect Disord 1998; 50: S3–9
   Google Scholar
• Young AS, Klap R, Sherbourne CD, Wells KB. The quality of care for depressive and anxiety disorders in the United States. Arch Gen Psychiatry 2001; 58(1)55–61
   PubMed Web of Science ®Google Scholar
• Wang PS, Berglund P, Kessler RC. Recent care of common mental disorders in the United States: Prevalence and conformance with evidence-based recommendations. J Gen Intern Med 2000; 15(5)284–92
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed, revised (DSM-III-R). Washington, DC: American Psychiatric Association; 1987.
   Google Scholar
• Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996; 11(Suppl 3)89–95
   PubMed Web of Science ®Google Scholar
• Ansseau M, Fischler B, Dierick M, et al. Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxemburg: The GADIS study. Eur Psychiatry 2005; 20(3)229–35
   PubMed Web of Science ®Google Scholar
• Lader M, Stender K, Burger V, Nil R. 2004. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: Randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2005; 19(4)241–8
   Google Scholar
• Weiller E, Bisserbe JC, Maier W, Lecrubier Y. Prevalence and recognition of anxiety syndromes in five European primary care settings. A report from the WHO study on psychological problems in general health care. Br J Psychiatry 1998; 173(Suppl 34)18–23
   Web of Science ®Google Scholar
• Schneier FR, Johnson J, Hornig CD, et al. Social phobia. Comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry 1992; 49(4)282–8
   PubMed Web of Science ®Google Scholar
• Kushner MG, Sher KJ, Beitman BD. The relation between alcohol problems and the anxiety disorders. Am J Psychiatry 1990; 147(6)685–95
   PubMed Web of Science ®Google Scholar
• Stein MB, Fuetsch M, Muller N, et al. Social anxiety disorder and the risk of depression: A prospective community study of adolescents and young adults. Arch Gen Psychiatry 2001; 58(3)251–6
   PubMed Web of Science ®Google Scholar
• Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol 2005; 12(Suppl 1)1–27
   PubMed Web of Science ®Google Scholar
• Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry Task Force on treatment guidelines for anxiety, obsessive-compulsive and posttraumatic stress disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 2002; 3: 171–99
   PubMedGoogle Scholar
• Kasper, S, Danzinger, R, Kapfhammer, HP, Biebl, W, et al., editors. Angststörungen – Medikamentöse Therapie. State of the Art 2004. Clinicum Psy Sonderausgabe, November 2004.
   Google Scholar
• Liebowitz MR, Stein MB, Tancer M, et al. A randomized, double–blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 2002; 63(1)66–74
   PubMed Web of Science ®Google Scholar
• Shelton CI. Long-term management of major depressive disorder: Are differences among antidepressant treatments meaningful?. J Clin Psychiatry 2004; 65(Suppl 17)29–33
   Google Scholar
• Stein MB, Fyer AJ, Davidson JR, et al. Fluvoxamine treatment of social phobia (social anxiety disorder): A double-blind, placebo-controlled study. Am J Psychiatry 1999; 156(5)756–60
   PubMed Web of Science ®Google Scholar
• Kasper S. Depression and anxiety – Separate or continuum? Editorial. World J Biol Psychiatry 2001; 2: 162–3
   PubMedGoogle Scholar
• Muller JE, Koen L, Seedat S, Stein DJ. Social anxiety disorder: Current treatment recommendations. CNS Drugs 2005; 19(5)377–91
   Google Scholar
• Kasper S, Resinger E. Panic disorder: The place of benzodiazepines and selective serotonin reuptake inhibitors. Eur Neuropsychopharmacol 2001; 11: 307–21
   PubMed Web of Science ®Google Scholar
• Nutt DJ. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr 2005; 10(1)49–56
   PubMed Web of Science ®Google Scholar
• Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005; 17(2)65–9
   Google Scholar
• Kasper S, Stein DJ, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder: Randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 2005; 186: 222–6
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Nil R, Dürr-Pal N, et al. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 2005; 66: 1270–8
   PubMed Web of Science ®Google Scholar
• Sánchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C. Escitalopram versus citalopram: The surprising role of the R-enantiomer. Psychopharmacology (Berlin) 2004; 174(2)163–76
   PubMed Web of Science ®Google Scholar